China Biotech Services Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for China Biotech Services Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	19.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Mar 07

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

Jan 18

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Jan 06

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Dec 09

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Aug 24

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Nov 05

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Oct 13

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Jun 28

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

Mar 16

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Dec 01

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Jul 26

China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Apr 05

Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Mar 23

Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Feb 23

Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

Jan 28

What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

Jan 11

The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Dec 08

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Biotech Services Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:8037 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	212	-95	132	195	N/A
9/30/2023	776	33	N/A	N/A	N/A
6/30/2023	1,347	159	513	610	N/A
3/31/2023	1,598	208	N/A	N/A	N/A
12/31/2022	1,852	258	375	483	N/A
9/30/2022	1,394	74	N/A	N/A	N/A
6/30/2022	937	3	222	257	N/A
3/31/2022	854	53	N/A	N/A	N/A
12/31/2021	624	19	28	41	N/A
9/30/2021	614	113	N/A	N/A	N/A
6/30/2021	999	155	296	426	N/A
3/31/2021	797	54	N/A	N/A	N/A
12/31/2020	656	30	295	422	N/A
9/30/2020	564	-21	N/A	N/A	N/A
6/30/2020	62	-105	-57	-50	N/A
3/31/2020	58	-106	N/A	N/A	N/A
12/31/2019	59	-99	-38	-30	N/A
9/30/2019	62	-76	N/A	N/A	N/A
6/30/2019	65	-72	-38	-34	N/A
3/31/2019	67	-66	N/A	N/A	N/A
12/31/2018	70	-64	-21	-15	N/A
9/30/2018	75	-95	N/A	N/A	N/A
6/30/2018	79	-83	-45	-40	N/A
3/31/2018	88	-48	N/A	N/A	N/A
12/31/2017	105	-63	-62	-57	N/A
9/30/2017	111	-48	N/A	N/A	N/A
6/30/2017	113	-64	N/A	-11	N/A
3/31/2017	104	-103	N/A	N/A	N/A
12/31/2016	87	-86	N/A	-25	N/A
9/30/2016	69	-81	N/A	N/A	N/A
6/30/2016	52	-84	N/A	-90	N/A
3/31/2016	39	-72	N/A	N/A	N/A
12/31/2015	34	-54	N/A	-85	N/A
9/30/2015	3	-36	N/A	N/A	N/A
6/30/2015	38	-21	N/A	-19	N/A
3/31/2015	56	-43	N/A	N/A	N/A
12/31/2014	70	-75	N/A	-40	N/A
9/30/2014	111	-85	N/A	N/A	N/A
6/30/2014	92	-84	N/A	-78	N/A
3/31/2014	89	-79	N/A	N/A	N/A
12/31/2013	85	-60	N/A	-42	N/A
9/30/2013	81	-44	N/A	-32	N/A
6/30/2013	113	15	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8037's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if 8037's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 8037's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8037's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 8037's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8037's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

China Biotech Services Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

China Biotech Services Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

China Biotech Services Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Nine Months Ended 30 September 2022

China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Recent updates

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.27 profit in FY 2022)

China Biotech Services Holdings Limited announced that it expects to receive HKD 88 million in funding

China Biotech Services Holdings Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

New major risk - Share price stability

Pengbo (Hainan) Medical Technology Co., Ltd. Announces the Approval by the Hainan Provincial Medical Products Administration

Executive Chairman & Compliance Officer recently bought HK$64k worth of stock

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Third quarter 2023 earnings released: HK$0.037 loss per share (vs HK$0.17 profit in 3Q 2022)

China Biotech Services Holdings Limited to Report Q3, 2023 Results on Nov 13, 2023

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Second quarter 2023 earnings released: HK$0.016 loss per share (vs HK$0.11 profit in 2Q 2022)

New minor risk - Share price stability

China Biotech Services Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

China Biotech Services Holdings Limited to Report First Half, 2023 Results on Aug 11, 2023

New minor risk - Market cap size

Executive Chairman & Compliance Officer recently bought HK$105k worth of stock

Executive Chairman & Compliance Officer recently bought HK$105k worth of stock

China Biotech Services Holdings Limited Announces Redesignation of Chui Hoi Yam from an Executive Director to Non-Executive Director

Executive Chairman & Compliance Officer recently bought HK$139k worth of stock

China Biotech Services Holdings Limited Declares Final Dividend for the Year Ended 31 December 2022

First quarter 2023 earnings released: HK$0.016 loss per share (vs HK$0.036 profit in 1Q 2022)

Upcoming dividend of HK$0.01 per share at 1.0% yield

Full year 2022 earnings released: EPS: HK$0.27 (vs HK$0.02 in FY 2021)

Investor sentiment improves as stock rises 22%

China Biotech Services Holdings Limited announced that it expects to receive HKD 77.8 million in funding from Guoyuan Securities Investment (Hong Kong) Limited

China Biotech Services Holdings Limited Announces Board Changes

Less than half of directors are independent

China Biotech Services Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Nine Months Ended 30 September 2022

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

China Biotech Services Holdings Limited to Report Q3, 2022 Results on Nov 14, 2022

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Second quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.023 in 2Q 2021)

China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

China Biotech Services Holdings Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment deteriorated over the past week

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Investor sentiment improved over the past week

China Biotech Services Holdings Limited Announces Management Changes

China Biotech Services Holdings Limited, Annual General Meeting, Jun 20, 2022

First quarter 2022 earnings released: EPS: HK$0.036 (vs HK$0.002 in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: EPS: HK$0.02 (vs HK$0.031 in FY 2020)

Investor sentiment improved over the past week

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

China Biotech Services Holdings Limited Announces Completion of First Patient Enrollment in Phase I Clinical Trial for Treatment of Relapsed/Refractory CD20-Positive B-Cellnon-Hodgkin Lymphoma

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS HK$0.003 (vs HK$0.064 in 3Q 2020)

Second quarter 2021 earnings released: EPS HK$0.023 (vs HK$0.019 loss in 2Q 2020)

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Insider recently bought HK$44m worth of stock

Investor sentiment improved over the past week

Compliance Officer & Executive Director has left the company

First quarter 2021 earnings released: EPS HK$2.00 (vs HK$0.023 loss in 1Q 2020)

Investor sentiment improved over the past week

China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS HK$0.031 (vs HK$0.10 loss in FY 2019)

Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

China Biotech Services Holdings Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

New 90-day high: HK$1.53

Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

Insider recently bought HK$10m worth of stock

China Biotech Services Holdings Limited Announces Shanghai Longyao Receives the Approval Letter for Clinical Trial from the National Medical Products Administration for the Company's Product Named Ly007 Cellular Injection

What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?